Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

hra-pharma switzerland sàrl - mitotanum - tabletten - mitotanum 500 mg, maydis amylum, cellulosum microcristallinum, macrogolum 3350, silica colloidalis anhydrica, pro compresso. - symptomatische behandlung des fortgeschrittenen (nicht-resezierbaren, metastasierenden oder rezidivierenden) nebennierenrindenkarzinoms - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

hra-pharma switzerland sàrl - ulipristalii acetas - tablet - ulipristalii acetas 30 mg, lactosum monohydricum 237 mg, povidonum k 30, carmellosum natricum conexum corresp. natrium 1.35 mg, magnesii stearas, pro compresso. - notfallkontrazeption innerhalb von 5 tagen - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

hra-pharma switzerland sàrl - ulipristalii acetas - filmtablette - ulipristalii acetas 30 mg, lactosum monohydricum 237 mg, povidonum k 30, carmellosum natricum conexum corresp. natrium 1.35 mg, magnesii stearas, Überzug: poly(alcohol vinylicus), macrogolum 3350, talcum, e 171, polysorbatum 80, e 172 (flavum), kalii aluminii silicas, pro compresso obducto. - notfallkontrazeption innerhalb von 5 tagen - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

hra-pharma switzerland sàrl - metyraponum - kapseln - metyraponum 250.00 mg, macrogolum 400, glycerolum (85 per centum), aqua purificata, macrogolum 4000, kapselhülle: gelatina, glycerolum (85 per centum), e 171, e 215 0.71 mg, ethylvanillinum, propylis parahydroxybenzoas natricus 0.35 mg, 4-methoxyacetophenonum, drucktinte: e 120, aluminii chloridum hexahydricum, natrii hydroxidum, hypromellosum, propylenglycolum, pro capsula corresp. natrium 0.13 mg. - adrenocorticostaticum - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

hra-pharma switzerland sàrl - levonorgestrelum - tabletten - levonorgestrelum 1.5 mg, lactosum monohydricum 90.9 mg, maydis amylum, povidonum k 30, silica colloidalis anhydrica, magnesii stearas, pro compresso. - hormonales kontrazeptivum zur schwangerschaftsverhütung in notfällen - synthetika

Europäische Union - Deutsch - EMA (European Medicines Agency)

hra pharma rare diseases - ketoconazole - cushing-syndrom - antimykotika zur systemischen anwendung - ketoconazole hra ist indiziert zur behandlung des endogenen cushing-syndroms bei erwachsenen und jugendlichen ab 12 jahren.

Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

1 a pharma gmbh (8013083) - lamotrigin - tablette - teil 1 - tablette; lamotrigin (23895) 25 milligramm

Europäische Union - Deutsch - EMA (European Medicines Agency)

rad neurim pharmaceuticals eec sarl - melatonin - schlaf initiation und wartung störungen - psycholeptika - circadin ist als monotherapie zur kurzzeitbehandlung von primären schlafstörungen indiziert, die sich durch eine schlechte schlafqualität bei patienten ab 55 jahren auszeichnen.

Europäische Union - Deutsch - EMA (European Medicines Agency)

taw pharma (ireland) limited - clopidogrel-hydrochlorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antithrombotische mittel - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

meda pharmaceuticals switzerland gmbh - pyridostigmini bromidum - dragees - pyridostigmini bromidum 60 mg, maydis amylum, magnesii stearas, amylum pregelificatum, povidonum k 30, silica colloidalis anhydrica, talcum, Überzug: acaciae gummi, paraffinum perliquidum, paraffinum solidum, oryzae amylum, saccharum 161,569 mg, talcum, e 172 (rubrum), e 172 (flavum) pro compresso obducto. - vagotonicum, antimyasthenicum - synthetika